Can Antiseizure Medications Cause Hyponatremia?
Yes, antiseizure medications (ASMs) are well-documented causes of hyponatremia, with certain agents carrying substantially higher risk than others.
Highest Risk Agents
The evidence clearly establishes that oxcarbazepine and carbamazepine pose the greatest risk for hyponatremia among ASMs 1. Guideline-level evidence from the American Academy of Neurology specifically documents that 21.6% of patients developed hyponatremia with oxcarbazepine versus only 2% with placebo 2. This represents a more than 10-fold increased risk.
Recent real-world data confirms:
- Oxcarbazepine-induced severe hyponatremia (≤128 mmol/L) occurs in 8.4% of patients 3
- Eslicarbazepine (a related dibenzazepine) causes hyponatremia in 30.5% of patients overall, with 6.1% developing severe hyponatremia 4
- The severity and prevalence are dose-dependent for these agents 4
Other Implicated ASMs
Beyond the dibenzazepines, additional ASMs associated with hyponatremia include:
- Valproic acid 5
- Carbamazepine - with higher serum levels significantly associated with lower sodium levels 6
- Phenytoin - higher serum concentrations correlate with reduced sodium 6
- Levetiracetam (though less commonly) 7
Key Risk Factors to Identify
When assessing hyponatremia risk in patients on ASMs, prioritize these factors:
Patient-specific risks:
- Older age - the single most important patient risk factor 4
- Concurrent diuretic use 3
- Polypharmacy with valproate, beta-blockers, calcium channel blockers, or other ASMs 3
- High ASM dosage 3
- History of stroke 3
Medication-specific risks:
- Multiple ASM therapy significantly increases risk 6
- Combination therapy with other sodium-lowering agents
Clinical Presentation and Monitoring
Acute hyponatremia (<48 hours) presents with:
- Delirium and seizures
- Decerebrate posturing
- Cerebral edema with potential uncal herniation 5
Chronic hyponatremia (>48 hours) manifests as:
- Lethargy, dizziness, weakness
- Headache, nausea, confusion 5
Critical caveat: Most cases are asymptomatic, particularly with eslicarbazepine where 48% require no management 4. However, hyponatremia is associated with longer hospital stays and increased mortality 5.
Management Algorithm
Step 1: Exclude other causes of hyponatremia before attributing to ASM 1
Step 2: Assess severity and symptoms
- Mild (130-134 mEq/L): Often asymptomatic, may observe
- Moderate (125-129 mEq/L): Consider intervention
- Severe (≤124 mEq/L): Requires active management
Step 3: Choose intervention based on severity
For asymptomatic mild hyponatremia:
- Conservative monitoring may be appropriate 1
- Consider sodium chloride supplementation (1-2 g/day reduces incidence but not severe cases) 8
For symptomatic or moderate-to-severe hyponatremia:
- Fluid restriction 1
- Discontinue other sodium-lowering medications where possible 1
- Reduce ASM dose if seizure control permits 1
- Switch to alternative ASM with lower hyponatremia risk (e.g., from oxcarbazepine to levetiracetam or lamotrigine) 1
Step 4: Balance seizure control versus sodium correction The decision must weigh the risks of untreated hyponatremia against disrupting seizure control 1. Patient preference should inform this decision 1.
Common Pitfalls
- Failing to monitor sodium levels in high-risk patients (elderly, on oxcarbazepine/carbamazepine, receiving polypharmacy)
- Assuming all hyponatremia is symptomatic - most cases are asymptomatic 4
- Overly aggressive sodium correction - rapid correction carries its own risks
- Not considering ASM switch when hyponatremia is recurrent or severe
- Overlooking drug interactions - particularly with diuretics, valproate, and cardiovascular medications 3